"The Precice Bone Transport System enables the treatment of complex segmental defects using the proven, less invasive, Precice magnetic technology which is a game-changer for my practice and patients," said Dr. J. Tracy Watson, professor of orthopedic surgery, University of Arizona College of Medicine—Phoenix, and the CORE Institute. "Patients who undergo a bone transport procedure due to trauma, tumors or infection are already dealing with significant issues regarding their condition, and the extreme time commitment it takes to reconstruct these significant bone defects. To be able to offer a treatment option that allows them to avoid many of the traditional complications and physical challenges of dealing with an external fixation system that is on their limb for an extended period of time is a significant development."
The Precice Bone Transport System includes an implantable, magnetic intramedullary nail with a dual slot designed to support the transport of an intercalary bone segment to facilitate healthy regeneration. Following implantation, an external remote controller is used to precisely move the bone segment up to 10 centimeters based on the specific needs of each patient. The Precice Bone Transport System provides an all-internal solution compared to traditional external fixation systems which require patients to wear an external device for an extended period of time, with the potential for increased pain and risk of infection.
Indications for the Precice Bone Transport System include treatment of acute bone defects up to 10 centimeters. The stainless steel device provides the strength and stability needed to treat more complex segmental defects due to trauma or infection including, but not limited to, infected non-unions, segmental defect, and chronic bone infections. The bone transport device uses proven Precice magnetic technology which is also used in the Precice Stryde System, an intramedullary limb-lengthening system cleared by the FDA and CE marked in 2018 for limb lengthening of the femur and tibia.
"The FDA clearance and CE mark approval for use of the Precice Bone Transport System are an exciting step forward for NSO as we continue to demonstrate how our innovative technologies can transform the orthopedic trauma space. With this clearance, we are now able to offer surgeons an all-internal, reliable treatment option that provides a simple approach to salvage both limbs and joints for complex limb reconstructions, such as patients with invasive tumors or large segmental defects," said Massimo Calafiore, president of NSO. "We remain committed to the ongoing development of innovative orthopedic solutions that equip surgeons to fulfill unmet clinical needs and, ultimately, improve the lives of patients."
The Precice Bone Transport System is expected to launch commercially in the U.S. and Europe in third quarter 2019.